For patients presenting with a ST-segment elevation myocardial infarction (STEMI), early myocardial reperfusion by primary percutaneous coronary intervention (PPCI) remains the most effective treatment strategy for limiting myocardial infarct size, preserving left ventricular systolic function, and preventing the onset of heart failure. Recent advances in PCI technology to improve myocardial reperfusion and the introduction of novel anti-platelet and anti-thrombotic agents to maintain the patency of the infarct-related coronary artery continue to optimize PPCI procedure. However, despite these improvements, STEMI patients still experience significant major adverse cardiovascular events. One major contributing factor has been the inability to protect the heart against the lethal myocardial reperfusion injury, which accompanies PPCI. Past attempts to translate cardioprotective strategies, discovered in experimental studies to prevent lethal myocardial reperfusion injury, into the clinical setting of PPCI have been disappointing. However, a number of recent proof-of-concept clinical studies suggest that the heart can be 'conditioned' to protect itself against lethal myocardial reperfusion injury, as evidenced by a reduction in myocardial infarct size. This can be achieved using either mechanical (such as ischaemic postconditioning, remote ischaemic preconditioning, therapeutic hypothermia, or hyperoxaemia) or pharmacological (such as cyclosporin-A, natriuretic peptide, exenatide) 'conditioning' strategies as adjuncts to PPCI. Furthermore, recent developments in cardiac magnetic resonance (CMR) imaging can provide a non-invasive imaging strategy for assessing the efficacy of these novel adjunctive therapies to PPCI in terms of key surrogate clinical endpoints such as myocardial infarct size, myocardial salvage, left ventricular ejection fraction, and the presence of microvascular obstruction or intramyocardial haemorrhage. In this article, we review the therapeutic potential of 'conditioning' to protect the heart against lethal myocardial reperfusion injury in STEMI patients undergoing PPCI.
Introduction
Coronary heart disease is the leading cause of morbidity and mortality in Europe and Worldwide. Its major emergent manifestation is a ST-segment elevation myocardial infarction (STEMI), which accounts for 800 hospital admissions every year per million population in Europe. 1 For STEMI patients, early myocardial reperfusion using primary percutaneous coronary intervention (PPCI) remains the most effective treatment strategy for reducing myocardial infarct (MI) size, preserving left ventricular (LV) ejection fraction, and preventing the onset of heart failure. The total ischaemic time (a key determinant of MI size) has been dramatically reduced by improvements in patient flow through the STEMI chain of survival, 2 resulting in shortened symptomonset to balloon times. Furthermore, recent developments in PCI technology (thrombus aspiration, novel stents), antiplatelet agents (Abciximab, Prasugrel, Ticagrelor), and anti-thrombotic agents (Bivalirudin) continue to optimise the process of myocardial reperfusion by maintaining the patency of the infarct-related coronary artery after PPCI. However, despite these improvements, the mortality of STEMI patients undergoing PPCI in Europe remains significant (3−7% in-hospital mortality depending on the country). 1 One major contributing factor has been the inability to protect the myocardium against the detrimental effects of lethal myocardial reperfusion injury during the PPCI procedure.
Although myocardial reperfusion is clearly essential for salvaging viable myocardium in STEMI patients, the actual process of restoring coronary blood flow to acutely ischaemic myocardium can paradoxically induce cardiomyocyte death in itself − a phenomenon which has been termed 'lethal myocardial reperfusion injury. 3, 4 The existence of lethal myocardial reperfusion injury as an independent mediator of cardiomyocyte death has been surrounded by controversy. 3, 4 Evidence supporting its existence as a cause of cell death distinct from acute myocardial ischaemia has been recently provided by experimental and more recently clinical studies reporting that MI size can be reduced by a therapeutic intervention given solely at the onset of myocardial reperfusion. 4 These studies suggest that lethal myocardial reperfusion injury accounts for 40−50% of the final MI size and its presence, therefore, mitigates the full benefits of reperfusion in terms of myocardial salvage. 4 There currently exists no effective therapeutic strategy for preventing lethal myocardial reperfusion injury in STEMI patients undergoing PPCI. Therefore, novel cardioprotective strategies, which can be administered to STEMI patients prior to or at the time of PPCI to prevent lethal myocardial reperfusion injury, are required to reduce MI size and preserve LV ejection fraction. In this regard, it is possible to 'condition' the heart to protect itself against acute ischaemia-reperfusion injury (IRI), through the activation of pro-survival intracellular signal transduction pathways which converge and protect against mitochondrial dysfunction during myocardial reperfusion. 5, 6 In this article, the therapeutic potential of 'conditioning' as a strategy for protecting the heart against lethal myocardial reperfusion injury in STEMI patients undergoing PPCI is reviewed.
Conditioning the heart to protect itself against ischaemia-reperfusion injury
A landmark experimental study published in 1986 by Murry et al. 7 first introduced the concept of ischaemic preconditioning (IPC) as a powerful endogenous therapeutic strategy for rendering the myocardium resistant to MI. These authors made the intriguing discovery that the canine heart could be protected against MI by subjecting it to four 5-min cycles of alternating occlusion and reflow of the left anterior descending (LAD) coronary artery (to induce episodes of brief myocardial ischaemia and reperfusion). 7 The IPC stimulus is believed to put the heart into a protected state through the activation of a number of complex intracellular signalling pathways, many of which converge on the mitochondria. 5, 6 However, the need to apply the IPC stimulus prior to the index myocardial ischaemic event and the requirement to apply the IPC stimulus to the heart directly has hampered its translation into the clinical setting. These obstacles have been overcome by the introduction of ischaemic postconditioning, 8 an endogenous cardioprotective strategy which can be applied at the time of myocardial reperfusion, and remote ischaemic perconditioning, 9 an endogenous cardioprotective strategy which can be applied after the onset of myocardial ischaemia to an organ or tissue remote from the heart, facilitating the translation of 'ischaemic conditioning' to STEMI patients undergoing PPCI.
Ischaemic postconditioning: cardioprotection at the time of reperfusion
In 2003, Zhao et al. 8 first introduced the concept of ischaemic postconditioning (IPost), an endogenous cardioprotective intervention which could be applied at the onset of myocardial reperfusion immediately following the index myocardial ischaemic event. Using the in-situ canine heart subjected to 60 minutes of LAD occlusion, these authors demonstrated that interrupting myocardial reperfusion with three 30-second cycles of LAD re-occlusion and reflow reduced MI size by 43%. 8 The fact that an intervention applied at the onset of myocardial reperfusion could limit MI size by over 40% confirmed the existence of lethal myocardial reperfusion injury and suggested that the latter was responsible for over 40% of the final MI size. Curiously, the term 'ischaemic postconditioning' was actually first mentioned in the research literature in 1996 by Na et al. 10 who first reported that ventricular premature beat-driven intermittent reperfusion could reduce reperfusion-induced ventricular fibrillation following myocardial ischaemia in feline hearts. Similarly, the idea of modifying the conditions of reperfusion to alleviate the detrimental effects of lethal myocardial reperfusion injury had been initially explored in the 1980s with controlled, gradual, or gentle reperfusion. 11, 12 All things considered, IPost, as a form of modified reperfusion, has regenerated interest in the reperfusion phase as a target for cardioprotection.
Only 2 years after its initial description, the concept of IPost was successfully translated into the clinical setting by Staat et al. in 2005. 13 In this first proof-of-concept clinical study, 30 carefully selected STEMI patients who were eligible for PPCI were randomised to receive either an IPost or sham protocol immediately following direct stenting to the infarct-related artery 13 (Table 1) . For those patients treated with IPost, the coronary angioplasty balloon was pulled immediately upstream of the stent and inflated to a low pressure (4−6 atm) for 60 seconds and then deflated for 60 seconds, a cycle which was repeated four times in total.
Interrupting myocardial reperfusion in the infarct-related coronary artery in this way was shown to reduce 72 h total creatine kinase area under the curve by 36%. 13 This landmark clinical study confirmed the existence of lethal myocardial reperfusion injury in man and suggested that the latter may contribute up to 40% of the final MI size in STEMI patients undergoing PPCI. Since the publication of this small initial clinical study, several other studies have been published confirming the beneficial effects of IPost both acutely and in the long-term using SPECT 56 , cardiac MRI 58 , and echocardiography 56 (Table 1) . However, a couple of recent clinical trials have been negative ( Table 1 ). The reason for the discordant findings in the recently published studies is not clear, although it may be attributed to a number of factors including:
(1) Comorbidities: In the experimental literature, it has been suggested that presence of certain comorbidities such as diabetes, hypertension, age, and dyslipidaemia can attenuate the efficacy of IPost. 14 Whether this phenomenon occurs in the clinical setting is unclear at present and needs to be addressed in a large multicentre randomised clinical trial of IPost; (2) Ischaemic time; It is not clear whether IPost is more effective in STEMI patients presenting with total ischaemic times (symptom-onset to balloon) of short (<3 h) or long (>3 h) duration. In other words, how the magnitude of lethal myocardial reperfusion injury varies with the preceding duration of ischaemia is not known. The experimental literature has reported that, in the rat MI model at least, IPost may actually be harmful following short ischaemic times (15−20 minutes) and only protective after longer durations of ischaemia (45−60 minutes). 15 Whether, a similar phenomenon is observed in the clinical setting is unknown; (3) Thrombolysis in myocardial infarction (TIMI) flow in the infarct-related coronary artery: It is vital that IPost is administered to those STEMI patients in which myocardial reperfusion has already not taken place spontaneously (i.e. TIMI flow within the infarct-related artery should be 0 at the time of PPCI). It has been estimated that 25−30% of patients treated by PPCI may have already undergone spontaneous lysis prior to coronary angiography; 16 (4) Coronary collateralisation: It is essential that STEMI patients with significant collateralisation to the area at risk are excluded at the time of coronary angiography as their presence would be expected to reduce MI size and may dilute the effect of IPost; (5) Area at risk(AAR): It is essential that the AAR of myocardial infarction is measured at the time of PPCI so that the efficacy of IPost can be assessed in terms of myocardial salvage, a measure which takes into account the differing sizes of the AAR between patients in the IPost and sham groups; (6) The size of the AAR: By including STEMI in all coronary territories there is a risk of diluting the beneficial effect of IPost. Ongoing clinical studies of IPost and other reperfusion treatment strategies have suggested that those STEMI patients presenting with a large AAR (>30% of LV) are most likely to accrue any benefit from IPost. 17 Similarly, patients with an AAR of <20% LV are unlikely to benefit from a cardioprotective intervention applied at PPCI. 17 Proximal LAD occlusions and some large right coronary artery (RCA) occlusions are most likely to have AAR >30% LV and these are the patients which should be targeted by IPost; (7) The delivery of the IPost protocol: Care must be given when applying the IPost protocol particularly in the presence of obvious thrombus in the infarctrelated coronary artery, as this could easily cause coronary embolization and worsen microvascular obstruction. For this reason, it is essential that the IPost protocol is performed upstream of the stent and not inside it.
Overall, the evidence suggests that IPost is cardioprotective in STEMI patients treated with PPCI. However, whether IPost can improve clinical outcomes in this patient group remains to be investigated in a large adequately powered multicentre clinical trial. In this regard, the DANAMI-3 trial (www.clinicaltrials.gov: NCT01435408), which is scheduled to report in 2014, is currently investigating whether IPost can improve clinical outcomes in PPCI patients ( Table 1) .
The disadvantages of IPost include: it prolongs the PPCI procedure, it requires a specific and carefully delivered protocol, and it can only be implemented in STEMI patients undergoing PPCI. Most importantly, IPost requires an interventional procedure being applied to the heart directly. This can be avoided by using a related endogenous cardioprotective strategy termed remote ischaemic conditioning, which was actually first described in 1993, 18 but has only been translated into the clinical setting in the last few years.
Remote ischaemic perconditioning in STEMI patients undergoing PPCI
In 1993, Przyklenk et al. 18 first demonstrated that applying four 5-minute cycles of occlusion and reflow to the circumflex coronary artery could reduce MI generated by a sustained occlusion in the LAD coronary artery, demonstrating for the first time that cardioprotection could be transferred from one region of the heart to another. This concept was quickly extended beyond the heart with the demonstration that the myocardium could be protected against MI by applying the preconditioning stimulus to either the kidney or intestine, 19 confirming that the heart could be protected at a distance. Remote ischaemic preconditioning, as it became termed, offered inter-organ protection from acute IRI. 20 Despite intensive investigation, the mechanistic pathway linking the preconditioning organ or tissue to the heart is unknown but it has been attributed to a neurohormonal pathway. 20−22 The next major development in the experimental literature was the discovery that the heart could be protected remotely by applying the remote ischaemic preconditioning (RIPC) stimulus to the lower limb, 23, 24 providing a noninvasive and practical approach for remotely protecting the heart. In 2002, Kharbanda et al. 25 first pioneered a noninvasive RIPC protocol in human volunteers, in which a standard blood pressure cuff was placed on the upper arm and inflated to 200 mmHg to and deflated to 0 mmHg to induce three 5-min cycles of ischaemia and reperfusion to the skeletal tissue of the lower arm, using flow mediated dilatation as the read-out. Furthermore, it was found that the remote ischaemic conditioning stimulus could be applied either prior (RIPC) to, or after the onset of (RIPerC) the index myocardial ischaemia 9 or even at the onset of myocardial reperfusion (RIPost), 26 facilitating its application to a wide variety of clinical settings of IRI, 20 including cardiac bypass 27, 28 and abdominal aortic aneurysm surgery, 29 elective percutaneous coronary intervention, 30 and most recently, STEMI patients undergoing PPCI. 31−33 At the beginning of 2010, two independent clinical studies were published investigating the effect of RIPerC in STEMI patients undergoing PPCI. 31, 32 In the study by Rentoukas et al., 31 96 STEMI patients were randomised at the hospital to receive control (three 4-min inflations to 20 mmHg below diastolic blood pressure and deflations to 0 mmHg of upper arm cuff started 10 min before reperfusion), RIPerC (three 4-min inflations to 20 mmHg above systolic blood pressure and deflations to 0 mmHg of upper arm cuff started 10 min before reperfusion) or RIPerC+morphine (5 mg intravenous infusion initiated 5 min before reperfusion). Interestingly, patients receiving RIPerC+morphine prior to PPCI had better ST-segment resolution, lower peak tropinin I levels compared to control patients. In those STEMI patients who received RIPerC alone, there was a non-significant trend to benefit when compared to control patients. 31 In the larger study by Botker et al., 32 the STEMI patients were randomised in the ambulance to receive control (a deflated cuff placed on the upper arm for 40 min) or RIPerC (four 5-min inflations to 200 mmHg and deflations to 0 mmHg of upper arm cuff). Because patients in the ambulance were randomised prior to coronary angiography and as the primary endpoint was myocardial salvage index at 30 days post PPCI estimated by gated single photon emission CT (SPECT), although 333 patients were randomised, only 142 patients were analysed for the primary endpoint of myocardial salvage. 32 Those patients randomised to RIPerC had a greater myocardial salvage index when compared to control (0.75 vs. 0.55, p=0.0333), although there was no significant difference in final MI size at 30 days (4% vs. 7% of LV, p=0.1). 32 However, in those patients presenting with LAD STEMI and complete occlusion in the infarct-related coronary artery (TIMI 0 flow), in whom the AAR was greater, there was a greater reduction in final MI size at 30 days in those patient treated with RIPC when compared to control (8% vs. 16% of LV with LAD STEMI, p=0.01 and 9% vs. 13% of LV with TIMI 0, p=0.06), despite there being little difference in the myocardial salvage index. 32 It is important to note there were no significant differences in important secondary outcomes including peak tropinin T, ST-segment resolution, LVEF at 30 days, 32 although a post-hoc analysis did observe a modest improvement in LVEF at 30 days in those patients with AAR >35% or those with LAD infarcts. 33 How the timing of the RIPerC protocol impacts on the cardioprotective effects of RIPerC is unclear. In the study by Rentoukas et al., 31 the RIPerC protocol was initiated in the cardiac catheter laboratory 10 minutes prior to the first angioplasty balloon inflation and it overlapped with reperfusion. In contrast, in the study by Botker et al., 32 the RIPerC protocol was delivered in the ambulance by paramedics, as the transit times are longer in Denmark, one may expect the earlier application to be more effective, which may in part explain the different in results between the two studies. Further studies are needed to confirm the cardioprotective benefits of RIPerC particularly in those patients most likely to benefit. Whether, the improved myocardial salvage conferred by RIPerC translates into improved clinical outcomes post PPCI remains to be determined in a large multicentre randomised clinical trial. Furthermore, whether RIPerC is effective in STEMI patients undergoing myocardial reperfusion using thrombolytic therapy, a group of patients not amenable to IPost, is unknown at present.
Several other mechanical cardioprotective strategies, which also recruit some of the signalling pathways utilized in IPost, and which have shown therapeutic potential when applied as adjuncts to PPCI, include therapeutic hypothermia and hyperbaric hyperoxaemia ( Table 2) . Of these two, therapeutic hypothermia is currently been investigated in the ongoing CHILL-MI study (www.clinicaltrials.gov: NCT01379261).
Pharmacological conditioning as an adjunct to PPCI
A number of pharmacological agents designed to prevent lethal myocardial reperfusion injury by targeting one of its individual components have been investigated as adjuncts to PPCI. Unfortunately, the results from the vast majority of these clinical studies have been hugely disappointing. The reasons for this are multifactorial and include inconclusive experimental studies, the timing of the intervention, and the patient selection (issues that are discussed in Table 3 and a later section). However, the elucidation of the signal transduction pathways underlying IPost have identified several novel targets for cardioprotection, a few of which have shown benefit in initial proof-of-concept clinical studies ( Table 4 ). The most promising of these pharmacological adjuncts include natriuretic peptide, 34 cyclosporin A, 35 and exenatide. 36 Further studies are required to confirm the efficacy of these therapeutic agents and to determine whether they can improve clinical outcomes in STEMI patients undergoing PPCI. In this regard, the CIRCUS study will investigate whether cyclosporin A can improve clinical outcomes in this patient group.
Cardiac MRI for assessing efficacy of adjunctive therapy in PPCI patients
Cardiac magnetic resonance (CMR) imaging of STEMI patients after they have undergone PPCI which is safe in the first week following PPCI, has emerged as an important imaging modality. From a clinical perspective in the first 2−3 days post PPCI, the CMR scan can be used to exclude LV thrombus, measure acute MI size, LV chamber size and ejection fraction, and assist in the diagnosis of troponinpositive chest pain where the coronary angiogram is normal such as in myocarditis. Repeated imaging at 3−6 months post PPCI permits the assessment of final MI size and ejection fraction after post MI remodelling. CMR imaging can also be used to detect the presence of microvascular obstruction 37 and intramyocardial haemorrhage, 38 key features of lethal myocardial reperfusion injury, which are associated with worse clinical outcomes following PPCI. Crucially, CMR can be used to assess myocardial salvage of novel cardioprotective strategies given as adjuncts to PPCI. Experimental animal studies have shown that 2 days following reperfusion of an acute MI in the canine heart, the area of myocardial oedema detected by T2-weighted CMR imaging corresponded to the AAR, assessed by the gold-standard technique of fluoroscopic microspheres. 39 In PPCI patients, the increase in signal intensity detected by T2-weighted CMR imaging in the first week following the STEMI, corresponded to the AAR delineated by myocardial nuclear scanning, 40 the current gold-standard technique for assessing AAR in the clinical setting. A couple of clinical studies have already applied T2-weighted imaging for the assessment of the AAR in order to index infarct size to the AAR 41 or to estimate myocardial salvage 36 when investigating novel adjuncts to PPCI. This area of research is not without controversy with experimental animal studies suggesting that T2-weighted CMR imaging overestimates the AAR; 42 questions over the validity of using an indirect measure such as myocardial oedema to depict the AAR; and whether the T2-weighted CMR imaging technique is robust enough in the acutely unwell PPCI patient to measure AAR. Whether the development of more robust T2 mapping CMR sequences 43, 44 or other novel CMR sequences 45 will facilitate use of CMR to retrospectively determine the AAR and therefore be used to measure myocardial salvage in PPCI patients remains to be determined.
Improving the translation process for clinical cardioprotection
Apart from early myocardial reperfusion, there is no other therapeutic strategy for limiting MI size in STEMI patients. Since the possibility of infarct-size limitation was first proposed in the late 1960s, a vast number of therapeutic agents have been identified in experimental studies to limit MI size. However, the vast majority of these treatments have not been translated into the clinical setting (Table 3 ). There are many reasons for this failure to translate cardioprotective therapies from the experimental setting to the clinical arena, and many of these have been discussed in the published literature 46−50 and reviewed in the section on ischaemic postconditioning. To summarize the key issues, the main obstacles to translation include the use of experimental animal MI models which poorly represent the STEMI patient undergoing PPCI, the failure to thoroughly test the novel treatment agent in the preclinical setting before moving onto clinical studies, and finally the design of the clinical studies. In 2004, the National Heart, Lung, and Blood Institute (NHLBI) first convened a workshop to discuss this issue, 46 and in 2010 proposed the formation of the US multicentre Consortium for Preclinical Assessment of Cardioprotective Therapies (CAESAR), which was set up to test novel cardioprotective strategies in small and large animal MI models using a multicentre randomised controlled 'clinical' trials approach. 51 This initiative will hopefully result in only the most robust cardioprotective strategies reaching the clinical setting.
Conclusions
Despite early reperfusion and improvements in anti-platelet and thrombotic therapy, the mortality of STEMI patients undergoing PPCI remains significant. One major contributing factor is the inability to protect the heart against the detrimental effects of lethal myocardial reperfusion injury, which occur on restoring blood flow to the acutely ischaemic myocardium. Previous attempts to prevent lethal myocardial reperfusion injury using pharmacological adjuncts to PPCI have been disappointing. However, a number of novel therapeutic strategies, which have been demonstrated in experimental studies to 'condition' the heart to protect itself against lethal myocardial reperfusion injury, have been reported in clinical proof-of-concept studies to prevent lethal myocardial reperfusion injury, as evidenced by reduced MI size and improved LV function. The more promising amongst these include mechanical 'conditioning' strategies such as ischaemic postconditioning, remote ischaemic perconditioning, therapeutic hypothermia or hyperoxaemia, and pharmacological 'conditioning' strategies such as natriuretic peptide, cyclosporin-A, and exenatide. Large multicentre studies are now required to investigate preventing lethal myocardial reperfusion injury using these novel therapeutic strategies improve clinical outcomes in STEMI patients undergoing PPCI. 
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